Clinical studies of moxalactam in complicated urinary tract infections.
Moxalactam in a daily dose of 0.5-2 g was administered for five days to 276 patients with complicated urinary tract infections. A satisfactory clinical response was obtained in 71% of the patients. All patients responded well except for those with infections caused by Streptococcus faecalis and Pseudomonas species, including Pseudomonas aeruginosa. Adverse reactions were observed in six patients (2.2%), but no adverse reaction required discontinuation of treatment. Abnormal results in clinical laboratory tests were found in four patients. Thus, it appears that moxalactam is a reliable and useful antibiotic for the treatment of complicated urinary tract infections.
D000368:Aged; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009070:Moxalactam; D018805:Sepsis / Q000382:microbiology; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam